Close

Form 6-K Centogene N.V. For: Oct 03

October 3, 2022 8:00 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the date of October 3, 2022

 

Commission File Number 001-39124

 

Centogene N.V.

(Translation of registrant's name into English)

 

Am Strande 7
18055 Rostock

Germany
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F..X..     Form 40-F.....

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

Centogene N.V.

 

On October 3, 2022, Centogene N.V. issued a press release titled “CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics”.

 

A copy of the press release is attached hereto as Exhibit 99.1.

 

 

 

 

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: October 3, 2022

 

CENTOGENE N.V.

 
       
       
By: /s/ Jose Miguel Coego Rios  
  Name: Jose Miguel Coego Rios  
  Title: Chief Financial Officer  

 

 

 

 

Exhibit Index

 

Exhibit Description of Exhibit
   
99.1 Press Release dated October 3, 2022

 

 

 

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings